Pedro Martinez-Clark is a world-renowned physician in Miami, Florida. Having earned his medical degree at Colombia’s acclaimed Universidad del Norte in the city of Barranquilla, Pedro traveled to Ohio’s Case Western Reserve University to begin his post-graduate medical training in Internal Medicine. Having excelled and made a name for himself in the northeast, Dr. Martinez-Clark placed into one of the United States’ most competitive Clinical Fellowships in Cardiovascular Disease (Cardiology), at Beth Israel Deaconess Medical Center, Harvard Medical School. At Harvard, he obtained further fellowship training in Interventional Cardiology, Endovascular Therapies and Vascular Medicine. During his stay at Harvard, Dr. Martinez-Clark participated in many clinical trials, research projects and started his involvement in medical device innovation. It would be no surprise that 8 years later, Dr. Martinez-Clark would become recognized, globally for excellence in medical care, research efforts and medical innovation contributions. In addition to caring for patients, Dr. Martinez-Clark works very closely with several public and private organizations with the common goal of improving the healthcare innovation ecosystem in South Florida.
From the medical innovation perspective, Dr. Martinez-Clark has been involved in several medical device development efforts. Some of these technologies include:
-Microprocessor controlled percutaneous aortic valve replacement which allows unparalleled precision and low tissue-device contact force at the time of implantation. This project has completed chronic animal experiments and is currently undergoing a second round of funding in order to start human trials.
-Percutaneous annuloplasty for the treatment of functional mitral regurgitation in patients with heart failure. The global clinical trial has been completed and the data has been submitted to the European Committee for device registration.
-Trans-Apical annuloplasty for the treatment of functional mitral regurgitation using a hybrid combined approach of surgical and percutaneous techniques. Feasibility study in humans has been completed.
-One of the original researchers that described the transcaval access to the cardiovascular system, a novel percutaneous approach that allows patients with peripheral vascular disease undergo percutaneous procedures with minimal risk. Dr. Martinez-Clark co-founded TransCaval Solutions, Inc, a medical device company dedicated to create purpose built access and closure technology that facilitates the transcaval access. The technique won the Best of the Best Abstract Award at The Society for Cardiovascular Angiography and Interventions (SCAI)'s 2014 meeting. Dr. Martinez-Clark obtained funding from private investors to develop and market his medical device to treat over 154,000 patients annually who can not be treated with conventional technical devices, thus creating a $ 2.2 billion market opportunity in 2020.
Objective To address, in a practical way, the acute treatment of ischemic cerebrovascular accident CVA based on the scientific recommendations latest. Methods A bibliographic search was performed in the PubMed, Scopus, Scielo and Uptodate database from January 2012 to April 2018, using the descriptors stroke , early management , therapeutic , intravenous thrombolysis , combined treatment , mechanical thrombectomy and its combinations. The selection of the articles was made by listing those of greater relevance according to the proposed theme, both in the foreign and Brazilian literature, in a non systematic way. Results Intravenous thrombolysis with recombinant tissue plasminogen activator rtPA within 4.5 hours of onset of symptoms is considered the therapy of choice in eligible patients. According to the new guidelines, mechanical thrombectomy can be performed within 24h and, for prevention of subsequent ischemic events, revascularization between 48h and seven days of the index event in candidate patients is reasonable. Conclusions As an essential cause of death and disability in the world, acute ischemic stroke treatment has advanced rapidly in recent years, improving therapeutic methods and their combinations. In clinical practice, recognizing, stratifying and listing, quickly and effectively, the best therapy for stroke patients is paramount. Renato Serquiz E Pinheiro | Yanny Cinara T Ernesto | Irami Araújo-Neto | Fausto Pierdoná Guzen | Amália Cinthia Meneses Do Rêgo | Irami Araújo-Filho ""Ischemic Brain Vascular Accident: Acute Phase Management"" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-3 | Issue-3 , April 2019, URL: https://www.ijtsrd.com/papers/ijtsrd23499.pdf
Paper URL: https://www.ijtsrd.com/biological-science/neurobiology/23499/ischemic-brain-vascular-accident-acute-phase-management/renato-serquiz-e-pinheiro
Irina Gontschar and Igor Prudyvus
Abstract
Introduction: The purpose of the study is to provide information about the database of 1421 adult patients with acute ischemic stroke (IS) developing ≤ 48 hours before admitting, research methods, study protocol, and clinical predictors of the evolving stroke course (EIS).
Methods and Materials: EIS outlined as an increase of NIHSS ≥ 2 points within seven days or in-hospital lethal outcome. Clinical, demographic, instrumental, laboratory data acquisition, as well as the IS course variant and the functional outcome assessment, were carried out prospectively. Statistical analyses were performed using R V.3.2.5 statistical package software and IBM SPSS Statistics 26.0.
Results: The incidence of EIS reached 30.0%. The average age of patients with EIS was 72.6±10.2 years, compare the age of patients without EIS - 68.1±11.3 years; p = 0.005. Female sex increased the odds of EIS (OR, 1.36; 95% CI 1.08-1.73). Total anterior carotid stroke (OR, 7.78; 95% CI 5.91-10.23), the initial NIHSS score > 14 points (OR, 3.74; 95% CI 2.83-4.94), and the right anterior circulation was also associated with EIS (OR, 1.30; 95% CI 1.02-1.66). The odds of EIS were significantly higher in the presence of diabetes mellitus (OR, 1.29; 95% CI 1.01-1.66), cerebral artery stenosis ≥ 70% (OR, 1.96; 95% CI 1.30-2.93), atrial fibrillation (OR, 1.89; 95% CI 1.51-2.39), congestive heart failure (OR, 1.90; 95% CI 1.51-2.39), and peripheral artery disease (OR, 1.69; 95% CI 1.27-2.25). Respiratory (OR, 2.82; 95% CI 2.22-3.59), gastrointestinal (OR, 1.34; 95% CI 1.05-1.70), and urologic diseases (OR, 2.10; 95% CI 1.65-2.66), stroke-associated infection (OR, 3.47; 95% CI 2.09-5.76), and gradual development of initial IS symptoms before admitting increased the odds of progression of the neurological deficit during treatment (OR, 2.37; 95% CI 1.78-3.15)were associated with the evolving clinical course of IS. The patients with the EIS compared with patients without EIS, showed higher serum levels of glucose (p < 0.001), urea (p = 0.001), creatinine (p < 0.001), sodium (p = 0.025), and direct bilirubin (p = 0.015). Potassium level in EIS group was lower than in the group without EIS (p < 0.001). In patients with EIS, a higher amount of RBC (p = 0.030) and WBC (p < 0.001) was found.
Conclusion: The in-hospital database contains information about EIS by the bases subtypes of IS, patient demography, cardiovascular risk factors, comorbid pathology, clinical and laboratory tests, instrumental methods of examination, medications, the severity of neurological deficit, and post-stroke outcome.
Percutaneous Coronary Intervention [PCI] has been a revolutionary advance in cardiology, and many lives have been saved as a result of the widespread application of primary PCI. However, elective PCI has not yet been proven to save lives or reduce the risk of myocardial infarction. Despite this lack of
evidence, elective PCI has been misused and in some cases, abused for nonmedical reasons. The considerable cost of elective PCI can be reduced, and the resources could potentially be utilized for better public health outcomes. The following.article intends to highlight the lack of evidence supporting the use of elective PCI, which is a problem not only in North America and Europe but also throughout the world.
Better regulation of the elective PCI procedure could reduce health care expenditures and divert resources to cardiovascular disease prevention.
Through the Eyes of Taiwanese Palliative Care Providers: End-of-life Treatmen...inventionjournals
The growth of medical knowledge and enhanced technology has increasingly blurred the line between life and death. Resuscitation procedures and life-sustaining devices such as mechanical ventilators, defibrillators, hemodialysis, and parenteral nutrition were introduced just a few decades ago, but have brought significant changes to the treatment of EOL patients. These treatments have given physicians the ability to prolong the process of dying; yet, the decision of when and how to use them has become complicated. An understanding of these controversial life-sustaining procedures and knowledge of current legal guidelines in the American EOL treatment context is necessary when palliative care in Taiwan seems to follow the Western experience in legislation regarding life-sustaining treatment. In this article, how EOL decisions made in the United States is summarized through the eyes of Taiwanese palliative care providers.
Role of Left Ventricular Mass Index Versus Left Ventricular Relative Wall Thi...Premier Publishers
In non-cardioembolic stroke patients, the cardiac manifestations of elevated blood pressure are of particular interest. The value of LV geometry in the prediction of cardiovascular risk is controversial. Many reports detected that left ventricular hypertrophy is independently associated with risk of ischemic stroke. The primary objective of this study was to identify the frequency of different patterns of altered left ventricular geometry in patients with non cardioembolic stroke, and to assess whether a significant number of patients will miss the diagnosis of LV remodeling if the left ventricular relative wall thickness(RWT) is not evaluated or reported. 100 patients were referred within 48 hours after an acute non cardioembolic ischemic stroke for a transthoracic echocardiogram. The echocardiographic findings were analyzed. Mean age was 61.86 ± 12.59 years, 45 % men. Concentric remodeling carried the highest frequency (43%), followed by normal pattern (27%), concentric hypertrophy (22%), and eccentric hypertrophy (8%). The frequency of abnormal left ventricular RWT (61.4%) was significantly higher than that of abnormal LVMI.
If you are looking for an experienced cardiologist in Jacksonville FL, you should search Dr. Manish Bansal in Jacksonville FL. Manish Bansal is an MD and also listed in topical specialist jacksonville on search places.
Objective To address, in a practical way, the acute treatment of ischemic cerebrovascular accident CVA based on the scientific recommendations latest. Methods A bibliographic search was performed in the PubMed, Scopus, Scielo and Uptodate database from January 2012 to April 2018, using the descriptors stroke , early management , therapeutic , intravenous thrombolysis , combined treatment , mechanical thrombectomy and its combinations. The selection of the articles was made by listing those of greater relevance according to the proposed theme, both in the foreign and Brazilian literature, in a non systematic way. Results Intravenous thrombolysis with recombinant tissue plasminogen activator rtPA within 4.5 hours of onset of symptoms is considered the therapy of choice in eligible patients. According to the new guidelines, mechanical thrombectomy can be performed within 24h and, for prevention of subsequent ischemic events, revascularization between 48h and seven days of the index event in candidate patients is reasonable. Conclusions As an essential cause of death and disability in the world, acute ischemic stroke treatment has advanced rapidly in recent years, improving therapeutic methods and their combinations. In clinical practice, recognizing, stratifying and listing, quickly and effectively, the best therapy for stroke patients is paramount. Renato Serquiz E Pinheiro | Yanny Cinara T Ernesto | Irami Araújo-Neto | Fausto Pierdoná Guzen | Amália Cinthia Meneses Do Rêgo | Irami Araújo-Filho ""Ischemic Brain Vascular Accident: Acute Phase Management"" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-3 | Issue-3 , April 2019, URL: https://www.ijtsrd.com/papers/ijtsrd23499.pdf
Paper URL: https://www.ijtsrd.com/biological-science/neurobiology/23499/ischemic-brain-vascular-accident-acute-phase-management/renato-serquiz-e-pinheiro
Irina Gontschar and Igor Prudyvus
Abstract
Introduction: The purpose of the study is to provide information about the database of 1421 adult patients with acute ischemic stroke (IS) developing ≤ 48 hours before admitting, research methods, study protocol, and clinical predictors of the evolving stroke course (EIS).
Methods and Materials: EIS outlined as an increase of NIHSS ≥ 2 points within seven days or in-hospital lethal outcome. Clinical, demographic, instrumental, laboratory data acquisition, as well as the IS course variant and the functional outcome assessment, were carried out prospectively. Statistical analyses were performed using R V.3.2.5 statistical package software and IBM SPSS Statistics 26.0.
Results: The incidence of EIS reached 30.0%. The average age of patients with EIS was 72.6±10.2 years, compare the age of patients without EIS - 68.1±11.3 years; p = 0.005. Female sex increased the odds of EIS (OR, 1.36; 95% CI 1.08-1.73). Total anterior carotid stroke (OR, 7.78; 95% CI 5.91-10.23), the initial NIHSS score > 14 points (OR, 3.74; 95% CI 2.83-4.94), and the right anterior circulation was also associated with EIS (OR, 1.30; 95% CI 1.02-1.66). The odds of EIS were significantly higher in the presence of diabetes mellitus (OR, 1.29; 95% CI 1.01-1.66), cerebral artery stenosis ≥ 70% (OR, 1.96; 95% CI 1.30-2.93), atrial fibrillation (OR, 1.89; 95% CI 1.51-2.39), congestive heart failure (OR, 1.90; 95% CI 1.51-2.39), and peripheral artery disease (OR, 1.69; 95% CI 1.27-2.25). Respiratory (OR, 2.82; 95% CI 2.22-3.59), gastrointestinal (OR, 1.34; 95% CI 1.05-1.70), and urologic diseases (OR, 2.10; 95% CI 1.65-2.66), stroke-associated infection (OR, 3.47; 95% CI 2.09-5.76), and gradual development of initial IS symptoms before admitting increased the odds of progression of the neurological deficit during treatment (OR, 2.37; 95% CI 1.78-3.15)were associated with the evolving clinical course of IS. The patients with the EIS compared with patients without EIS, showed higher serum levels of glucose (p < 0.001), urea (p = 0.001), creatinine (p < 0.001), sodium (p = 0.025), and direct bilirubin (p = 0.015). Potassium level in EIS group was lower than in the group without EIS (p < 0.001). In patients with EIS, a higher amount of RBC (p = 0.030) and WBC (p < 0.001) was found.
Conclusion: The in-hospital database contains information about EIS by the bases subtypes of IS, patient demography, cardiovascular risk factors, comorbid pathology, clinical and laboratory tests, instrumental methods of examination, medications, the severity of neurological deficit, and post-stroke outcome.
Percutaneous Coronary Intervention [PCI] has been a revolutionary advance in cardiology, and many lives have been saved as a result of the widespread application of primary PCI. However, elective PCI has not yet been proven to save lives or reduce the risk of myocardial infarction. Despite this lack of
evidence, elective PCI has been misused and in some cases, abused for nonmedical reasons. The considerable cost of elective PCI can be reduced, and the resources could potentially be utilized for better public health outcomes. The following.article intends to highlight the lack of evidence supporting the use of elective PCI, which is a problem not only in North America and Europe but also throughout the world.
Better regulation of the elective PCI procedure could reduce health care expenditures and divert resources to cardiovascular disease prevention.
Through the Eyes of Taiwanese Palliative Care Providers: End-of-life Treatmen...inventionjournals
The growth of medical knowledge and enhanced technology has increasingly blurred the line between life and death. Resuscitation procedures and life-sustaining devices such as mechanical ventilators, defibrillators, hemodialysis, and parenteral nutrition were introduced just a few decades ago, but have brought significant changes to the treatment of EOL patients. These treatments have given physicians the ability to prolong the process of dying; yet, the decision of when and how to use them has become complicated. An understanding of these controversial life-sustaining procedures and knowledge of current legal guidelines in the American EOL treatment context is necessary when palliative care in Taiwan seems to follow the Western experience in legislation regarding life-sustaining treatment. In this article, how EOL decisions made in the United States is summarized through the eyes of Taiwanese palliative care providers.
Role of Left Ventricular Mass Index Versus Left Ventricular Relative Wall Thi...Premier Publishers
In non-cardioembolic stroke patients, the cardiac manifestations of elevated blood pressure are of particular interest. The value of LV geometry in the prediction of cardiovascular risk is controversial. Many reports detected that left ventricular hypertrophy is independently associated with risk of ischemic stroke. The primary objective of this study was to identify the frequency of different patterns of altered left ventricular geometry in patients with non cardioembolic stroke, and to assess whether a significant number of patients will miss the diagnosis of LV remodeling if the left ventricular relative wall thickness(RWT) is not evaluated or reported. 100 patients were referred within 48 hours after an acute non cardioembolic ischemic stroke for a transthoracic echocardiogram. The echocardiographic findings were analyzed. Mean age was 61.86 ± 12.59 years, 45 % men. Concentric remodeling carried the highest frequency (43%), followed by normal pattern (27%), concentric hypertrophy (22%), and eccentric hypertrophy (8%). The frequency of abnormal left ventricular RWT (61.4%) was significantly higher than that of abnormal LVMI.
If you are looking for an experienced cardiologist in Jacksonville FL, you should search Dr. Manish Bansal in Jacksonville FL. Manish Bansal is an MD and also listed in topical specialist jacksonville on search places.
Mayo Clinic - 2011 ACC Satellite Education Symposiumswest0521
This is satellite educational symposium during the 2011 ACC Scientific Session. The program would be of interest for imaging professionals, cardiologists, radiologists, nuclear cardiology and nuclear medicine specialists and other healthcare providers interested in the application of cardiac imaging in clinical practice.
Heberden meticulously described a symptom, but he did not understand the disease. Edward Jenner noticed thickened coronary arteries at autopsy of his colleague John Hunter who had died suddenly after an angina attack in 1793,2 but it took decades for a first remedy for angina pectoris and even longer for a true understanding of the underlying disease
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
Pedro Martinez-Clark Feb 2016 CV
1. PEDRO MARTINEZ-CLARK, M.D. CURRICULUM VITAE
1. Date: February , 2016
I. PERSONAL
2. Name: Pedro Martinez-Clark, M.D.
Website: www.martinezclark.com
Work Title: Interventional Cardiologist, private practice
3. Phone Number: 617-216-0339
4. E-Mail: pmclark@interventionalconcepts.net
5. Mailing Address: 2520 Coral Way, Suite # 2120
Miami, FL 33145
6. Academic Rank: Voluntary Assistant Professor of Medicine
6a. Track: Clinical Track
7. Primary Department: Medicine – Interventional Cardiology –
8. Career Interest: Program development, medical innovation, clinical trials
II. HIGHER EDUCATION
9. Institutional:
1. Jan 1991 – June 1998: M.D., Universidad del Norte - Medical School Barranquilla, Colombia
2. July 1998 – Sept 1999: Research fellow Gastroenterology Division, Beth Israel Deaconess
Medical Center, Harvard Medical School.
3. October 1999 – Sept 2002: Resident, Internal Medicine, MetroHealth Medical Center, Case
Western Reserve University
4. October 2002 – Sept 2004: Clinical Fellow in Cardiovascular Diseases
Beth Israel Deaconess Medical Center, Harvard Medical School
5. Oct 2004 – Sept 2005: Clinical Fellow in Interventional Cardiology, Beth Israel Deaconess
Medical Center, Harvard Medical School – Specialty in Cardiovascular Diseases
6. Oct 2005 – Sept 2006: Clinical Fellow in Endovascular Therapies and Vascular Medicine
Beth Israel Deaconess Medical Center, Harvard Medical School
2. Pedro Martinezclark, M.D. Curriculum Vitae
2
10. Non-Institutional:
Clinical Training
1. Dec 2005: Non-invasive Vascular Imaging Certification. Vascular Medicine Division,
Cleveland Clinic Foundation, Cleveland, OH
2. Jan 2006: Radioactive Materials certification and Level 2 Nuclear Cardiology training, St.
Elizabeth Medical Center – Boston, MA
11. Certification
1. 2009: Interventional Cardiology Board Certification
2. 2008: Cardiovascular Disease Board Certification
3. 2008: State of Florida Full Medical License, # ME97003
4. 2006: Internal Medicine Board Certification
5. 2006: Radioactive Materials Florida License
III. EXPERIENCE
12. Academic: N/A
13. Active Hospital Appointments:
1. May 2008 - present: University of Miami Hospital, Staff Physician
2. July 2014 - present: Mercy Medical Center, Miami, Florida
3. July 2014 - present: Aventura Medical Center, Miami, Florida
4. May 2008 - December 2012: Jackson Memorial Hospital, Miami, Florida
5. October 2008 – December 2012: Lower Keys Medical Center. Key West, Florida
6. Dec. 2006 - Jan. 2009: Palm Beach Gardens Medical Center, Palm Beach Gardens, Florida
7. Dec., 2006-Jan. 09: Good Samaritan Hospital, West Palm Beach, Florida
8. Dec., 2006-Jan. 09: Jupiter Medical Center, Jupiter, Florida.
14. Military: N/A
3. Pedro Martinezclark, M.D. Curriculum Vitae
3
IV. PUBLICATIONS
15. Books, reviews and monographs:
1. Mechanical Interventions in Acute Myocardial Infarction. William O’Neill and Pedro
Martinezclark. Hurst The Heart, 13th
Edition, Ch 63, p 1457-1471.
16. Juried or refereed journal articles or exhibitions:
1. Spontaneous Coronary Artery Dissection: Case Series from two Institutions with Literature
Review. Carlos Esteban Uribe, Juan David Ramirez-Barrera, Carlos Rubio, Cesia Gallegos,
Luz Adriana Ocampo, Clara Saldarriaga, Carlos Eusse, Carlos Tenorio, Nilson Lopez, Andres
Moreno, Natalia Gomez Jaramillo, Alexander Morteza Chehrazi-Raffle, Vikas Singh, Pedro
Martinez-Clark. Anatol J Cardiol 2015; 15: 409-415
2. Transcaval transcatheter aortic valve implantation for severe aortic insufficiency. Singh
V, Martinez-Clark PO, Cadena J, Gallegos C, Dager A, Guerrero M, O'Neill WW.
Circulation. Cardiovascular interventions. 2014;7:723-725
3. Transcaval Retrograde Transcatheter Aortic Valve Replacement for Patients With no
Other Access. First in Man Experience With Corevalve. Pedro O. Martinez-Clark, MD,
Vikas Singh, MD, Jairo A. Cadena, MD, Angela Maria Cucalon Reyes, MD, Cesia Gallegos,
MD, Antonio Dager, MD, Adam Greenbaum, MD, William O’Neill, MD. JACC:
Cardiovascular Interventions. Vol 7, No 9, 2014.
4. Impact of CMS coverage decision on access to transcatheter aortic valve replacement.
Brian P O'Neill, William W O'Neill, Donald Williams, Mauricio G Cohen, Alan W Heldman,
Conrad Macon, Claudia A Martinez, Carlos E Alfonso, Pedro Martinez Clark, Omaida
Velasquez, David Seo, Pascal Goldschmidt Clermont, Mauro Moscucci. Catheter Cardiovasc
Interv. 2014 Jan 16. doi: 10.1002/ccd.25394
5. The Use of Vascular Closure Devices and Impact on Major Bleeding and Net Adverse
Clinical Events (NACE) in Balloon Aortic Valvuloplasty: A Sub-Analysis of the BRAVO
study. Brian O’Neill, Vikas Singh, Evan Jacobs, David Knopf, Carlos E. Alfonso, Claudia A.
Martinez, Pedro Martinezclark, Alan W. Heldman, Jennifer Yu, Usman Baber, Jason
Kovacic, George Dangas, Annapoorna Kini, Roxana Mehran, Samin Sharma, Samantha Sartori,
and Mauricio G. Cohen. Catheter Cardiovasc Interv. March 25, 2013.
6. Transseptal Antegrade Transcatheter Aortic Valve Replacement for Patients With No
Other Access Approach – A Contemporary Experience. Cohen MG, SinghV, Martinez CA,
O’Neill BP, Alfonso CE, Martinezclark P, Heldman AW, O’Neill WW. JACC Cardiovascular
Interventions. June 1, 2013
7. Management of Paravalvular Regurgitation After Edwards SAPIEN Transcatheter
Aortic Valve Replacement. Claudia A. Martinez, Vikas Singh, Brian O’Neill, Carlos E.
Alfonso, Martin S. Bilsker, Pedro MartinezClark, Donald Williams, Mauricio G. Cohen, Alan
W. Heldman, William W. O'Neill. Catheter Cardiovascular Interv August 1, 2013
4. Pedro Martinezclark, M.D. Curriculum Vitae
4
8. Retrograde Percutaneous Closure of a Ventricular Septal Defect after Myectomy for
Hypertrophic Obstructive Cardiomyopathy. Vikas Singh, Apurva O. Badheka, Edward
Ghersin, Pedro Martinez-Clark, William O. O’Neill.Texas Heart Journal. 468 (4) November
4, 2013
9. "Very Late Bare Metal Stent Thrombosis: Review of an Often Catastrophic Outcome".
Vikas Singh, Aarti Patel, Eric S Shaw, Pedro Martinezclark, William O’Neill. Valves &
Chambers, The journal of Cardiology. 2010; Sep;1:(3).
10. Cardiac Biomarkers - The Old and The New: A Review. Vikas Singh, Pedro
Martinezclark, Mario Pascual, Eric Shaw, W O’Neill. Coron Artery Dis. 2010 Jun;21(4):244-
56. Review.
11. “Very Late (10 year old) Bare Metal Stent Thrombosis” A Case Report. Eric Shaw, Vikas
Singh, Pedro Martinezclark, W O’Neill. Cardiovascular Division, University of Miami, Miller
School of Medicine. Cardiology. 2010;115(2):127-9.(DOI:10.1159/000261308)
12. Pedro Martinezclark, Martinez Natalia. ESTUDIO SYNTAX: Sinergia entre la cirugía bypass
y la intervención coronaria percutánea mediante el uso del stent TAXUS, December 2008
http://www.cardiosource.com/espanol/NewsOpinions/ExpertOpinions/detail.aspx?id=311&type
=ht
13. Pedro Martinezclark, Martinez Natalia. Avances en el manejo de la estenosis aórtica.
Alternativas percutáneas, December 2008
http://www.cardiosource.com/espanol/NewsOpinions/ExpertOpinions/detail.aspx?id=311&type
=ht
14. Clouse ME, Sabir A, Yoshimura N, Lin S, Welty F, Martinezclark P, Buros JL, Raptopoulos
V. Measuring Non-Calcified Coronary Atherosclerotic Plaque Using Voxel Analysis with
MDCTA: A Pilot Clinical Study. Am J of Roentgenol, Jun 2008; 190:1553-1560
15. Yeon SB, Sabir A, Clause M, Martinezclark PO, Peters DC, Gibson CM, Maintz D, Manning
WJ, Botnar RM. Delayed Enhancement MR Coronary Artery Wall Imaging: Comparison with
Multidetector CT and X-Ray Angiography. J Am Coll Cardiol 2007; 50(5): 441-447
16. Martinezclark P, Carrozza Jr. JP, Soluble Mediators of Microvascular Dysfunction-Identifying
the Invisible Culprits? J Invas Cardiol 2005; 17(11): 580-581
17. Kirtane AJ, Rahman A, Martinezclark P, Jeremias A, and Manning WJ. Survey of Practice
Patterns in the Management of Anticoagulation in Patients with Mechanical Valves Undergoing
Elective Outpatient Procedures, Am J Cardiol, 2006; 97(6): 891-3
18. Kirtane AJ, Martinezclark P, Rahman AM, Ray KK, Karmpaliotis D, Murphy SA, Giugliano
RP, Cannon CP, Antman EM, Roe MT, Harrangton RA, Ohman EM, Braunwald E, Gibson
CM. Association of smoking with improved myocardial perfusion and the angiographic
characterization of myocardial tissue perfusion after fibrinolytic therapy for ST-segment
elevation myocardial infarction. J Am Coll Cardiol 2005; 45(2): 321-3
19. Freedman SD, Westein D, Blanco PG, Martinezclark P, Urman S, Zahman M, Morrow JD,
Alvarez J. Pseudomonas LPS Induced Lung Inflammation Model in CFTR (-/-) mice and the
effect of docosahexaenoic acid. J Appl Physiol 2002; 92(5): 2169-76
5. Pedro Martinezclark, M.D. Curriculum Vitae
5
17. Other works, publications and abstracts:
Abstracts
1. Percutaneous closure of a ventricular septal defect after Myectomy for hypertrophic obstructive
cardiomyopathy. Singh V, Badheka AO, Bokhari SS, Ghersin E, MartinezClark P, O'Neill
WW. Transcatheter Cardiovascular Therapeutics (TCT) conference. 2012 October 22-26th
Miami Beach.
2. Impact of Vascular Closure With the Pre-Closure Technique on Adverse Events in Patients
Undergoing Transfemoral Balloon Aortic Valvuloplasty: Results from a 2-Center Registry.
Brian P. O'Neill, Vikas Singh, Jennifer Yu, David Knopf, Usman Baber, Claudia Martinez,
Carlos Alfonso, Jason Kovacic, George Dangas, Evan Jacobs, Annapoorna Kini, Roxana
Mehran, Samin Sharma, Pedro Martinez-Clark, Samantha Sartori, Alan Heldman, William
O'Neill, Mauricio Cohen. American College of Cardiology 61st Annual Scientific Session and
ACC-i2 with TCT, March 24-27, 2012 in Chicago, IL. J Am Coll Cardiol 2012;59:A57.
3. Contemporary Review of Conduction Disturbances in Balloon Aortic Valvuloplasty. Brian
O'Neill, Conrad Macon, Vikas Singh, Carlos Alfonso, Pedro Martinez-Clark, Alan W.
Heldman, Mauro Moscucci, Mauricio Cohen, William W. O'Neill, Claudia A.Martinez. M3
International Cardiovascular Conference. October 3-5, 2011. Miami, Florida
4. Contemporary Practice of Balloon Aortic Valvuloplasty in the Transcatheter Aortic Valve
Replacement Era. A Single High-Volume Center Experience. David Knopf, Brian P. O’Neill,
Vikas Singh, Evan Jacobs, Carlos E. Alfonso, Alan W. Heldman, Claudia A. Martinez-
Bermudez, Pedro O. Martinezclark, Eduardo de Marchena, William W. O’Neill, Mauricio G.
Cohen. M3 International Cardiovascular Conference. October 3-5, 2011. Miami, Florida.
5. David Knopf; Brian P. O’Neill; Vikas Singh; Evan Jacobs; Carlos E. Alfonso; Alan W.
Heldman; Claudia A. Martinez-Bermudez; Pedro O. Martinez-Clark; Martin Bilsker; Eduardo
de Marchena; William O’Neill; Mauricio G. Cohen. “Contemporary Practice of Balloon
Aortic Valvuloplasty in the Trans-Catheter Aortic Valve Replacement Era: A Single High-
Volume Center Experience”. SCAI M3 International Cardiovascular Conference, Miami, FL
October 3, 2011.
6. Brian O’Neill; Conrad Macon; Vikas Singh; Carlos Alfonso; Pedro Martinez-Clark; Alan
Heldman; Mauro Moscucci; Mauricio Cohen; William O’Neill; Claudia Martinez.
“Contemporary Review of Conduction Disturbances in Balloon Aortic Valvuloplasty”. SCAI
M3 International Cardiovascular Conference, Miami, FL October 3, 2011.
7. Juan P. Zambrano; Khalid M. Minhas; Carlos Alfonso; Alejandro Gonzalez; Pedro Martinez-
Clark. “Subintimal Angioplasty and Re-entry Technique as a Successful Approach to
Challenging Chronic Peripheral Total Occlusions: A Case Series”. SCAI M3 International
Cardiovascular Conference, Miami, FL October 3, 2011.
8. Pedro Martinezclark, Dimitri Karmpaliotis, Sabina A. Murphy, MPH; Stephen D. Wiviott,
Brian Bigelow, Ioanna Kosmidou, Allen Chang, Christopher P. Cannon, MD; Robert P.
Giugliano, MD, C. Michael Gibson, M.S., M.D. “The Association of Race with Angiographic
and Clinical Outcomes Following Fibrinolytic Administration. Abstract and oral presentation,
American College of Cardiology Scientific Sessions, 2004.
6. Pedro Martinezclark, M.D. Curriculum Vitae
6
18. Other works accepted for publication: N/A
V. PROFESSIONAL
19. Funded Research Performed: N/A
20. Editorial Responsibilities: N/A
21. Professional and Honorary Organizations:
1. American College of Cardiology
2. Society of Coronary Angiography and Interventions
3. Latin America Society of Interventional Cardiology
4. Society of Vascular Medicine
5. Colombian Society of Cardiology
6. Colombian Society of Interventional Cardiology
7. Caribbean Cardiology Society
22. Postdoctoral Fellowships:
1. 1998 – 1999: Research fellow Gastroenterology division, Beth Israel Deaconess Medical
Center, Harvard Medical School
23. Honors and Awards:
1. Society for Coronary Angiography and Interventions 2014. Best oral research presentation
award
2. Latino magna…….
24. Other Professional Activities (2007 – present)
Current Clinical Research:
1. Percutaneous Mitral Valve Annuloplasty. Feasibility trial testing the safety and efficacy of
percutaneous mitral annuloplasty using the Mitralign system in patients with functional mitral
regurgitation. Role: Worldwide Principal Investigator and currently the most experienced
operator. This project is in collaboration with Dr. Martin B Leon from the Cardiovascular
Research Foundation. We just completed the CE mark trial and are currently enrolling
patients for a 50 patient efficacy trial in 5 sites in Germany, Poland, Brasil, Colombia and
France. FDA IDE trial is scheduled for 2015.
7. Pedro Martinezclark, M.D. Curriculum Vitae
7
2. SPARE-MR: A Feasibility Study of the Safety and Efficacy of
SPanning Sutures for Anterior-Posterior Reduction to Eliminate Mitral Regurgitation
in Patients with Heart Failure. Role: First in man principal investigator in collaboration with
Dr. Howard Herrmann from the University of Pennsylvania School of Medicine. First in man
trial expected to start in June 2014.
3. Microactuator controlled percutaneous aortic valve system. Develop the scientific pathway
for testing, validation, safety and efficacy of the Syntheon Percutaneous Aortic Valve System in
animals and humans. Role: Currently medical director of Syntheon Cardiovascular.
Currently in starting chronic animal experiments and submitting for first in man acute
hemodynamic experiment for Q3 2015 pending funding.
4. COBRA PzF™ COronary Stent System in Native coronary arteries for early healing,
thrombus inhibition, endothelialization and avoiding long-term dual anti-platelet therapy:
Role: Principal investigator out of United States for all Latin America
5. Heart XS Device. Corquest Medical Role: Founder and board member. The company sold to
Cardio3 in November 2014
6. PARTNER: Placement of Aortic Transcatheter Valves Therapies. Randomized multicentric
clinical trial of percutaneous aortic valve implantation using the Saphien Edwards Valve. Co-
investigator.
7. Protect II: Randomized clinical trial using the Impella 2.0 mechanical support device in high-
risk patients undergoing percutaneous intervention. Co-investigator working with Dr. William
O’Neill. Completed and presented.
8. US Corevalve Pivotal Trial. Co-investigator
9. Direct-Flow Percutaneous Trans-catheter aortic valve system CE Mark trial. Role: Co-
investigator in the CE mark trial.
Invited Lectures:
2007
1. Syndrome X 2007 conference organizer and guest speaker for metabolic syndrome and
cardiovascular risk in Latin America, Mexico City.
2. Angiome X 2007, Conference organizer and guest speaker for Peripheral Vascular Disease
Awareness in Latin America, Mexico City
2008
1. Trans catheter Therapeutic Interventions 2008. Faculty. Washington, D.C.
2. Syndrome x 2008 Vulnerable Plaque, Course Director, August 1, 2008. Mexico City, DF
3. First Cardiovascular and Electrocardiographic Workshop Universidad del Norte. Course
director and speaker, Barranquilla, Colombia, South America, September 1, 2008.
8. Pedro Martinezclark, M.D. Curriculum Vitae
8
2009
1. New Percutaneous Valve Technology. Expert panel member, Medtronic Corporation,
Minneapolis, Minnesota, January 12, 2009
2. Transfemoral and Transapical Percutaneous Aortic Valve Replacement. Percutaneous Valve
Technology. Latin American Society of Thoracic Surgery. Guest Speaker, Cartagena,
Colombia, South America, February 13, 2009
3. New Technology in Chronic Total Occlusions. Miami International Revascularization Summit.
Speaker, Miami, Florida, February 21, 2009
4. Percutaneous Valve Technology. Thought Leaders Summit 2009. Guest Speaker, Hollywood,
Florida, March 13, 2009
5. Percutaneous Ventricular Assist Devices. Miami International Revascularization Summit, First
International Symposium, Hotel Hilton, Cartagena, Columbia, South America, May 1, 2009
6. First Interventional Cardiology Symposium, Manta, Ecuador, S.A. Invited speaker on
Percutaneous valve technology and percutaneous closure of patent foramen ovale. Manta,
Ecuador, May 22-24, 2009.
7. Mexican Cardiology Society. Invited Speaker. State of the Art Lecture of Percutaneous Valve
Technology. Mexico City, August 15, 2009.
8. Corevalve Simposium, Miami, F.L. October 9, 2009. Moderator.
9. Colombian Society of Interventional Cardiology. Invited Speaker. High Risk Coronary
Intervention. Barranquilla, Colombia, S.A. October 16 , 2009.
10. Colombian Society of Interventional Cardiology. Invited Speaker. Percutaneous Valve
Therapies. Barranquilla, Colombia, S.A. October 17, 2009.
2010
1. Percutaneous Aortic Valve Implantation. University of Miami Cardiovascular Congress,
February 26, 2010.
2. Percutaneous Treatment of Aortic Valve Disease. Valvular Symposium, Cali, Colombia. July
31, 2010.
3. Percutaneous Treatment of Aortic Valve Disease. Colombian Cardiovascular Society,
Barranquilla, Colombia, October 29, 2010.
4. Percutaneous Treatment of Mitral Valve. Colombian Cardiovascular Society, Barranquilla,
Colombia, October 29, 2010.
5. Mechanical Support Devices During High Risk Percutaneous Revascularization. Eight Annual
Masters in Repair of Structural Heart Disease. Miami, FL October 15, 2010.
9. Pedro Martinezclark, M.D. Curriculum Vitae
9
2011
1. Mechanical Support During High Risk Percutaneous Revascularization. Latin American
Cardiovascular Society Meeting. Cartagena, Colombia S.A. March 11, 2011.
2. Percutaneous Treatment of Valvular Heart Disease. Florida Osteopathic Medical Association.
Jacksonville, FL April 16, 2011.
3. Trans-catheter Aortic Valve Replacement. Baylor Cardiovascular Summit. May 7, 2011
4. High Risk Angioplasty and Mechanical Support. Caribbean Cardiovascular Society, Trinidad
and Tobago July 22, 2011.
5. Future Percutaneous Valve Technology. Valve Summit, Cali, Colombia S.A. July 29, 2011.
6. Mechanical Support During TAVI. Valve Summit, Cali, Colombia S.A. July 29, 2011.
7. New Technology for Safer Trans-Septal Puncture. SCAI M3 Meeting, Miami, FL October 4,
2011.
8. Future Devices for Left Atrial Appendage Closure. SCAI M3 Meeting, Miami, FL October 4,
2011.
9. New Trans-Catheter Valve Technology. Colombian Interventional Cardiology Society
Meeting. Bogota, S.A. October 28, 2011.
10. Percutaneous Left Atrial Appendage Closure. Colombian Interventional Cardiology Society
Meeting. Bogota, S.A. October 28, 2011.
2012
1. Lower Extremity Atherectomy. Thought a hands on training course on peripheral atherectomy
for physicians in Latin America. Mexico, April 23, 2012.
2. Percutaneous Valve Technology. Colombian Cardiovascular Symposium, Cali, Colombia. May
9, 2012.
3. Transcatheter Valve Technology. Cardiovascular Summit, Jacksonville, Florida. April 28,2012
2013
1. Left ventricular mechanical support in the cath lab. November 23, 2013, Colombia
Interventional Cardiology Society Meeting
2. Percutaneous Left atrial appendage closure: Rational for the procedure. November 23, 2013,
Colombia Interventional Society Meeting
2014
1. Percutaneous Mitral Annuloplaty for Mitral Repair in FMR. May 15, 2014, CATCH-UP 2014:
Heart Failure, Devices, and Interventions. New York Presbyterian/Columbia Unversity
Medical Center Vivian and Seymour Milstein Family Heart Center.
2. Percutaneous Treatment for Mitral and Tricuspid Valve Disease. May 21, 2014, Euro-PCR
2014. Guest speaker.
3. Didactic Symposia: Interventional Innovation II - TCT 2014 Innovation Award Competition -
10. Pedro Martinezclark, M.D. Curriculum Vitae
10
In Partnership with ICI and Stanford Biodesign TCT2014 Innovation Award Competition.
9/14/14. Syntheon Cardiology TAVR: Precise Control and Constant Force.
4. Didactic Symposia: Interventional Innovation II - TCT 2014 Innovation Award Competition -
In Partnership with ICI and Stanford Biodesign TCT2014 Innovation Award Competition.
9/14/14. Percutaneous Left Atrial Access Using the Novel Corquest HeartXS Device
25. Teaching Awards Received
First Time in Humans: Novel Venous Route Enables CoreValve Procedure in Patients
with Severely Clogged Arteries May 26, 2014. Best research award.
26. Teaching Specialization
1. General Cardiovascular Diseases
2. Interventional Cardiology
3. Structural Heart Disease
4. Endovascular Therapies
27. Innovation & Entrepreneurship
1. Corquest: Development of a percutaneous technology for accessing the heart directly from the
chest wall. Annimal and cadaver experiments successfully conducted and technology adquired
by Cardio3 Biosciences in November 2014. Chief Scientific Advisory Board
2. TransCaval Solutions: Described a new percutaneous approach for patients with peripheral
vascular disease. Developed purpose built medical devices for this procedure and closed the
first round of funding for TransCaval Solutions, INC. Founder.
3. Miami MedTech: The first healthcare specific incubator in South Florida. Founder.
4. Syntheon: Chief Medical Officer for Syntheon Cardiovascular LLC. Lead the scientific
strategy and development of a new percutaneous aortic valve system using microprocessors for
enhanced precision and control. Animal studies completed and currently raising fund for
second round of funding.
5. Interventional Concepts, INC: Founded the only contract research organization that facilitates
performing clinical trials in Latin America to early stage medical innovation start-up
companies.
28. Industry Consulting and Proctoring
1. Medtronic Corporation: National Medical Education Faculty. Part of a select group of
physicians in the United States that educates other physicians on new therapies and
technologies in interventional cardiology and endovascular therapies.
2. Saint Jude Medical: Consultant
3. AstraZeneca: National speaker bureau
4. Medtronic Corporation: Lead a successful proctoring course in percutaneous lower extremity
revascularization for complex total arterial occlusions using the sub-intimal re-entry technique
from 2009-2011.
5. Medtronic Corporation Latin American Division: International proctor for atherectomy in the
treatment of arterial peripheral vascular disease. 2009-2013.
11. Pedro Martinezclark, M.D. Curriculum Vitae
11
29. University committee and administrative responsibilities:
1. January 2009 – June 2009: Chair, ST elevation myocardial infarction process improvement
committee. University of Miami Hospital. Invited by Dr. William O’Neill.
2. January 2009 - December 2012: Ischemic Limb Program Steering Committee. University of
Miami Hospital. Invited by Dr. William O’Neill.March 2009-present
3. March 2009 – December 2012: Cardiovascular Process Improvement Committee. University
of Miami Hospital. Invited by Dr. William O’Neill.
30. Community Activities:
1. American Heart Association – Volunteer Community Educator
a. Hispanic Cardiovascular Health Outreach program
b. Educate minority groups on cardiovascular disease awareness
2. West Palm Beach Mayor’s Office Minority Health Initiative
a. Regular co-host on local NBC morning show “Hablando con la Comunidad” focusing on
health education for the Hispanic community.
VI. PROGRAM DEVELOPMENT INTEREST
1. Trans-Catheter Valve Replacement
2. Left Atrial Appendage Closure
3. Percutaneous Treatment of Mitral Valve Disease
4. Endovascular treatment of critical limb ischemia
VII. WORK HISTORY
01/2016 to present Pedro Martinez-Clark, MD, P.A.
2520 Coral Way, # 2120, Miami, FL 33145
Phone: (617) 216-0339 Fax (305)397-2986
07/2014 to 12/2015 Miami-Dade Cardiology Consultants, LLC
3801 Biscayne Boulevard, #300
Miami, FL 33137
Phone: (305) 571-0620 Fax (305) 576-8099
From 05/2013 to 7/2014 Pedro Martinez-Clark, M.D., P.A.
2520 Coral Way, # 2120, Miami, FL 33145
Phone: (617) 216-0339 Fax (305)397-2986
12. Pedro Martinezclark, M.D. Curriculum Vitae
12
From 10/2012 to Present Interventional Concepts, Inc.
2520 Coral Way, #2120
Miami, FL 33145
Phone: (617) 216-0339 Fax (305)397-2986
From 04/2008 to 01/2013 University of Miami-Dept of Medicine
1400 NW 10 Avenue
Miami, FL 33136
Phone : (305) 243-3015 Fax (305)243-3018
From 01/2007 to 01/2008 Palm Beach Cardiovascular Clinic
600 University Boulevard, #200
Jupiter, FL 33455
Phone : (561) 627-2210 Fax (561) 627-2130